Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,908 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Active Cancer Clear all
Completed Not applicable Interventional Results available

Consumer-Based Activity Monitor in Evaluating and Measuring Activity of Older Patients With Abdominal Cancer Undergoing Surgery

NCT02356471
View directory record Official record
Conditions
Malignant Gastrointestinal Neoplasm, Malignant Peritoneal Neoplasm
Interventions
Management of Therapy Complications Fitbit Zip (portable pedometer device), Questionnaire Administration, Quality-of-Life Assessment
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Sep 11, 2026, 2:29 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer

NCT00348816
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, prednisone, Radical prostatectomy, Radiation therapy
Drug · Procedure · Radiation
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 11, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors

NCT02304393
View directory record Official record
Conditions
Solid Tumors
Interventions
Atezolizumab, Selicrelumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 11, 2026, 2:29 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Promoting Physical Activity In After-School Programs for Urban Adolescents

NCT00301158
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
exercise intervention, counseling intervention, educational intervention, complementary or alternative medicine procedure
Behavioral · Other · Procedure
Lead sponsor
Montclair State University
Other
Eligibility
11 Years to 14 Years
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Montclair, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 16, 2013 · Synced Sep 11, 2026, 2:29 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

NCT04052204
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
avelumab, Bempegaldesleukin, talazoparib, enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 11, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

NCT03205176
View directory record Official record
Conditions
Malignant Solid Tumors, Lymphoma, Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
Interventions
AZD5153, Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Sep 11, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Results available

Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

NCT02432235
View directory record Official record
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Interventions
Camidanlumab tesirine
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
Duarte, California • New York, New York • Cleveland, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 11, 2026, 2:29 AM EDT
Terminated Not applicable Interventional Results available

Mobile Intervention - Physical Activity in Cancer Treatment

NCT03671304
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Fitbit Versa
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 11, 2026, 2:29 AM EDT
Terminated Not applicable Interventional

INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma

NCT03692338
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Exercise
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 11, 2026, 2:29 AM EDT
Completed Not applicable Interventional

Physical Activity, Fatigue, Sleep, and Inflammation

NCT01147367
View directory record Official record
Conditions
Breast Cancer
Interventions
3 month physical activity intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
30 Years to 70 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Sep 11, 2026, 2:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

NCT06554795
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
DB-1419
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Newport Beach, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 11, 2026, 2:29 AM EDT
Recruiting Not applicable Interventional

Precision Optical Guidance for Oral Biopsy

NCT05554133
View directory record Official record
Conditions
Oral Lesions
Interventions
High Resolution Microendoscope (HRME), Optical Mapping Scope, Proflavine hemisulfate
Device · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 11, 2026, 2:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Physical Activity in Young Adult Cancer Survivors

NCT03233581
View directory record Official record
Conditions
Physical Activity, Quality of Life
Interventions
Fitbit + Facebook + Coaching Group, Fitbit only
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Years to 39 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Sep 11, 2026, 2:29 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Home-Based Measures of Physical Activity and Body Composition

NCT00542438
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Physical Activity Recall, Environmental Assessments
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 11, 2026, 2:29 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT07095452
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig, Lenalidomide, Daratumumab, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2042
U.S. locations
17
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 11, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02737332
View directory record Official record
Conditions
Prostate Cancer
Interventions
Zytiga® (Abiraterone Acetate), SoluMatrix™ (Abiraterone Acetate)
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Laguna Hills, California • Los Angeles, California • San Bernardino, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 11, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

NCT02665416
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors
Interventions
Selicrelumab, Vanucizumab, Bevacizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Sep 11, 2026, 2:29 AM EDT
Completed Phase 2 Interventional

Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer

NCT00448409
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
TroVax, GM-CSF
Biological · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 11, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

NCT05867121
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
RO7496353, Atezolizumab, Capecitabine, S-1, Nivolumab, Oxaliplatin, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Los Angeles, California • New Haven, Connecticut • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 11, 2026, 2:29 AM EDT
Terminated No phase listed Observational

Outcome Assessment of an Active Surveillance Program for Low Risk Prostate Cancer: An Observational Study

NCT01376661
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
St. Joseph Hospital of Orange
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Sep 11, 2026, 2:29 AM EDT
Recruiting Phase 1 Interventional

A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3

NCT07807241
View directory record Official record
Conditions
Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
Interventions
MX006
Drug
Lead sponsor
Myricx Pharma Limited
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Sarasota, Florida • Houston, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 11, 2026, 2:29 AM EDT
Terminated Phase 2 Interventional Results available

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

NCT05814666
View directory record Official record
Conditions
HNSCC
Interventions
Danvatirsen, Pembrolizumab
Drug
Lead sponsor
Flamingo Therapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
21
States / cities
Tucson, Arizona • Irvine, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 11, 2026, 2:29 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

NCT03332797
View directory record Official record
Conditions
Breast Cancer
Interventions
GDC-9545, Palbociclib, LHRH Agonist
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 11, 2026, 2:29 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Fat Metabolism Following Chemotherapy in Breast Cancer

NCT01890824
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Texas A&M University
Other
Eligibility
30 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 11, 2026, 2:29 AM EDT